201 results about "Neurological function" patented technology

Methods and devices that provide ultrasonic energy used to cause one or more nerves to become dysfunctional. A nerve to be treated is placed in the focal zone of ultrasonic energy emitted by ultrasound transducer. A first level of ultrasonic energy is provided to the nerve using the ultrasound transducer, the first level sufficient to stimulate the nerve. A verification is made that the desired nerve is being stimulated by the first level of ultrasonic energy. For example, the patient may be asked to confirm that the ultrasonically stimulated nerve corresponds to the pain that is affecting the patient. Subsequent to verifying the stimulated nerve is the nerve desired for the reduction of pain, a second level of ultrasonic energy is delivered to the nerve using the ultrasound transducer, the second level of ultrasonic energy sufficient to cause nerve dysfunction.

Embodiments include methods and apparatus for determining whether a neurological event has occurred in a subject. An apparatus includes at least one sensor adapted to sense electroencephalogram signals from the subject. The apparatus also includes an electroencephalogram acquisition module adapted to receive the electroencephalogram signals from at least one sensor, and a processing and analysis module adapted to receive signals from the electroencephalogram acquisition module and determine changes in neurological function using entropy analysis.

An implantable device for treating a patient using sensory substitution includes a wearable article in which are disposed one or more sensors for detecting the phase of the gait cycle of the patient, a controller for receiving signals from the sensors indicative of the phase of the gait, and one more stimulators for stimulating the patient based on signals from the controller that are issued in response to the sensor signals.

A method, apparatus, and surgical technique for the modulation of autonomic function, for the purpose of treating any of several conditions and diseases, including obesity, metabolic disorders, endocrine disorders, diabetes, respiratory disease, asthma, inflammatory disease, immunological disease, infection, cancer, cardiac disease, cardiovascular disease, cerebrovascular disease, stroke, vasospasm, vascular disease, psychiatric disease, depression, affective disorders, anxiety disorders, and other conditions. This includes neural and tissue modulators, including implanted devices, used to modulate efferent and afferent autonomic neurons to influence or control autonomic or other neural function, including modulation of sympathetic and parasympathetic nervous system components as well as their combination.

A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and / or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and / or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and / or a cognitive retraining program, and / or a dietary program designed to maximize insulin and glucose metabolism.

A device for treating a patient using sensory substitution includes a wearable article in which are disposed one or more sensors for detecting the phase of the gait cycle of the patient, a controller for receiving signals from the sensors indicative of the phase of the gait, and one more stimulators for stimulating the patient based on signals from the controller that are issued in response to the sensor signals.

Methods, systems and devices are provided in which electromagnetic waves (EMWs) are applied to a neural target. The neuronal function of at least a portion of the neural target is monitored, and the effect of EMW application on neural properties, neural function, and / or neural disorders is assessed. Embodiments include methods of diagnosis, treatment, drug delivery, cognitive enhancement, and EMW stimulation systems.

A testing system and method for evaluation of neurological function are provided. Specifically, the system and method can be used to differentiate between normal and pathological function for motor skills, logic, reasoning, coordination, verbal function, memory, and various other skills. In addition, it is designed to provide a package to a clinician, including a recommended battery of tests and a results report. The system and method described herein is designed to reduce bias due to the human nature of the tester, while still maintaining versatility, individualized attention and depth of analysis in testing.

A system and method for determining the neurological function of a patient by examining ocular responses.

A method of presenting multiple image sources of approximately registered images so that the mind can easily fuse the multiple images into one image. Improvement to fusing can be achieved by alternating views between sources at 85 hertz or more. The insertion of a black frame between the succession of frames optimizes the neurological functions of the human optical system (produces retinal decay) such that the perception of a useful fused image is greatly enhanced. Stereographic fusion can also be achieved to allow for fusion of loosely registered datasets.

The invention discloses a mirror movement neuromodulation system, which comprises a plurality of lead biological signal amplifiers, a microcomputer controller, a plurality of lead functional electric stimulators and a micro-current direct-current constant-current stimulator. The principle that functional electric stimulation and transcranial direct-current electric stimulation techniques and mirror movement neurons participate in movement control is applied comprehensively, the biological signal amplifiers, the functional electric stimulators for simulating integrated electromyography envelope signal control, and the micro-current direct-current constant-current stimulator are integrated through the microcomputer controller, myoelectric activity envelope signals are generated by processing myoelectric signals of a plurality of muscle groups which move functionally by using an uninjured side limb, and the plurality of functional electric stimulators are modulated and controlled, so that the same mirror action is generated by the plurality of muscle groups of an injured limb on an opposite side according to uninjured side myoelectric information, brain functional regulation and reconstruction are realized, the plasticity of neuronal synapsis and the recovery of neurological functions are facilitated, and the treatment effect of sports rehabilitation is achieved.

Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury are disclosed.

A method and system for monitoring phrenic nerve function and preventing phrenic nerve injury during cardiac ablation. The system includes a pacing device operable to transmit stimulation energy to the phrenic nerve through target tissue proximate the phrenic nerve, a plurality of assessment electrodes operable to make comparisons between baseline, real-time, and predetermined threshold values for CMAP signal amplitude and amplitude over time. The processing device may be connected to an ablation console, and the processing device may interrupt or adjust an ablation procedure controlled by the ablation console and / or generate a system alert in response to one of these comparisons, if the comparison indicates phrenic nerve injury. The method includes applying stimulation energy to the phrenic nerve, recording diaphragmatic CMAP signals in response to the stimulation energy, and adjusting an ablation procedure and / or automatically generating a system alert in response to comparisons performed by the processing device.

An exoskeleton apparatus driven by a pneumatic artificial muscle with functions of upper limb assist and rehabilitation training includes an upper limb frame, a shoulder joint mechanism, and an elbow joint mechanism which are driven by utilizing a processing unit, a first angle sensing unit, a second angle sensing unit, a first proportional pressure valve, a pressure sensing unit and a pneumatic muscle device. The exoskeleton apparatus can be independently used as an upper limb exoskeleton assistive device or can be combined to form an upper limb exoskeleton rehabilitation training system to simulate the upper limb movements in daily life through the upper limb frame to assist with the movements of the wearer's upper limbs, accomplishing the rehabilitation training of each upper and lower arm joint and neurological function.

The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.

A method and apparatus for monitoring optic function is provided. The apparatus and method relies on two principle modes of measuring the function of the optic nerve, namely, monitoring VEPs for neural function, and monitoring at least one additional parameter of optic function such as intraocular pressure, blood flow or location of the eye to provide a multi-variable optic function monitor. The method and apparatus is proposed for the use to diagnose and potentially prevent the incidence of POVL and anaesthesia awareness in patients during medical procedures.

The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, in the prevention or treatment of injury to the brain after cerebral ischemia or neurological disorder. More particularly, the invention provides methods of improving neurological function and outcome after stroke by the administration of SCF polypeptide, alone and in combination with G-CSF polypeptide. This treatment can be used alone or in combination with other well-known methods of treatment of cerebral ischemia and neurological disorders in a mammal.

This invention relates to a method and apparatus for identifying degenerative disorders and particularly to the early and accurate diagnosis of Alzheimer's Disease.

Disclosed herein an improved systems and methods using point-of-care (POC), IoT (Internet of Things) enabled device(s) which captures different bio-signals simultaneously as distinct signals, by targeting same neurovascular substrate. The synchronized streaming of the data for live analysis or recording in the tele neuro-monitoring platform are jointly processed in an Artificial Intelligence (AI) based big-data platform under a closed loop, bi-directional, decision tree based system for brain / neurological function status monitoring (continuously and / or intermittently) leading to online POC diagnosis, severity classification, and prognosis of neurological disorders and neurovascular diseases.

Physostigmine, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5ol methylcarbamate, administered buccally or sublingually in non-sustained release dosage form provides extremely prolonged blood levels. This active agent is physically compounded with materials of some or all of classes of ingredients that function as pH controls, preservative agents, viscosity control agents, absorption enhancers, stabilizing agents, solvents, and carrier vehicles. This compounding will produce a pharmaceutical composition in the form of a liquid, tablet, gel, patch or lozenge for administration of the active agent, Physostigmine, by absorption through the buccal or sublingual mucosa of the patient. This method of delivery of Physostigmine and similar compounds is useful for treatment of cognitive deficiencies and / or neurological function deficits, mood and / or mental disturbances in mammals including human beings.

The present invention comprises the use of pharmaceutical compositions that are effective in the inhibition of the Na+ / H+ exchanger, subtype 5 (NHE-5) as inhibitors of cellular NHE-5 enhance long term potentiation (LTP) and are therefore effective in the treatment of memory impairments, dementing disorders, and for improving memory. Particularly suitable for the treatment of neurodegenerative disorders, memory impairments and dementing disorders, and for improving memory, are the following NHE-5 inhibitors of the formula IWherein the R1-R8 substituents are further defined herein:

Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual at least 1000 mg or more of L-dopa (levodopa) per day. The use of potent dopaminergic agents to stimulate emergence from an altered consciousness state, such as a coma, is disclosed.

This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and / or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.

A method for identifying a functional area of a brain. The functional area is associated with a neurological function. The method includes applying a plurality of electrodes to a surface of the brain. A slow cortical potential is determined based on one or more electrical signals produced by the plurality of electrodes. A covariance pattern is computed based on the slow cortical potential, and the configuration of co-varying electrodes is used to identify one or more areas of the brain associated with the neurological function. These co-varying patterns may be used in conjunction with other electrical and / or physiological stimulation paradigms.